DEF 14A: Onconetix Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

Onconetix is seeking stockholder approval for a reverse stock split to increase its stock price and regain compliance with Nasdaq listing requirements.

Summary

• Onconetix is holding a special meeting of stockholders on May 30, 2025, to vote on two proposals.
• The first proposal is to approve an amendment to the company's charter to effect a reverse stock split of its common stock at a ratio between 1-for-10 and 1-for-150.
• The second proposal is to approve the adjournment of the special meeting, if necessary, to solicit additional proxies if there are insufficient votes to approve the reverse stock split proposal.
• The board of directors unanimously recommends that stockholders vote FOR both proposals.
• The record date for determining stockholders eligible to vote at the special meeting is April 14, 2025.
• The company received a notice from Nasdaq indicating that it is not in compliance with the minimum bid price requirement of $1.00 per share.
• On April 14, 2025, Nasdaq issued a further notice to the Company that it determined that the Company's securities had a closing bid price of $0.10 or less for ten consecutive trading days.
• The company believes that a reverse stock split could help it regain compliance with Nasdaq listing requirements and improve its ability to conduct capital raising activities.
• If the reverse stock split is approved, the board will determine the final ratio and communicate it to the public.
• The reverse stock split will affect all holders of common stock uniformly and will not affect any stockholder's percentage ownership interests or proportionate voting power.
• The company does not intend to issue fractional shares in connection with the reverse stock split; instead, it will pay cash for fractional shares.
• The company has engaged Alliance Advisors to assist in the solicitation of proxies for the special meeting, and estimates that it will pay Alliance Advisors a fee of approximately $20,000, plus reimbursement for certain out-of-pocket fees and expenses.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting the facts of the proposed reverse stock split and the reasons behind it. While the company is facing delisting, the document focuses on the potential benefits of the reverse stock split and avoids overly optimistic or pessimistic language.

Positives

• A reverse stock split could help Onconetix regain compliance with Nasdaq listing requirements.
• A higher stock price could make the company more attractive to a broader range of investors.
• Increased investor interest could lead to greater liquidity and trading volume of the common stock.
• The reverse stock split will not affect stockholders' percentage ownership or voting power.
• The company will pay cash for fractional shares, avoiding the issuance of fractional shares.

Negatives

• The reverse stock split may not result in a sustained increase in the price of the common stock.
• The reverse stock split may decrease the liquidity of the common stock.
• Some stockholders may own odd lots after the reverse stock split, which may be more difficult to sell.
• The reverse stock split may lead to a decrease in the overall market capitalization of the company.

Risks

• The company may not be able to regain compliance with Nasdaq listing requirements even with the reverse stock split.
• The market price of the common stock may not increase following the reverse stock split.
• The reverse stock split may be viewed negatively by the market.
• The company's financial results and market conditions could adversely affect the market price of the common stock.

Future Outlook

The company aims to regain compliance with Nasdaq listing requirements through the reverse stock split. The board will determine the final ratio and timing of the split based on market conditions and other factors. The company may consider financing opportunities in the future, but has no current plans to issue additional shares beyond those related to existing securities and the equity line of credit.

Management Comments

• The Onconetix Board has unanimously determined and resolved that the Reverse Stock Split Proposal and the Adjournment Proposal are advisable and fair to, and in the best interests of, Onconetix and its stockholders, and has approved the Reverse Stock Split Amendment, subject to stockholder approval.
• Accordingly, the Onconetix Board unanimously recommends that Onconetix stockholders vote FOR each of the foregoing proposals.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low stock prices. The success of a reverse stock split depends on various factors, including the company's underlying financial performance and market sentiment. Other companies in similar situations may pursue similar strategies.

Comparison to Industry Standards

• Many companies facing Nasdaq delisting due to low share prices have implemented reverse stock splits.
• The range of reverse stock split ratios being considered by Onconetix (1-for-10 to 1-for-150) is within the typical range seen in similar situations.
• The success of a reverse stock split in maintaining listing and improving investor sentiment is highly variable and depends on the specific circumstances of the company.

Stakeholder Impact

• Shareholders may experience a change in the number of shares they own due to the reverse stock split.
• The reverse stock split could impact the liquidity and trading volume of the company's stock.
• Employees may be affected by the company's ability to maintain its Nasdaq listing and raise capital.
• The company's ability to attract and retain investors could be influenced by the reverse stock split.

Next Steps

• Stockholders will vote on the reverse stock split and adjournment proposals at the special meeting on May 30, 2025.
• The board will determine the final reverse stock split ratio, if approved, and communicate it to the public.
• The company will file the Reverse Stock Split Amendment with the Secretary of State of the State of Delaware, if approved by the stockholders and the Board decides to proceed.
• The company will continue to pursue efforts to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

reverse stock split, proxy statement, Onconetix, Nasdaq, compliance, stockholders, common stock, delisting, bid price, special meeting